|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT00219635 |
|
Date of registration:
|
09/09/2005 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation
|
|
Scientific title:
|
A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study To Assess The Efficacy and Safety Of Oral UK-390,957 In Men With Premature Ejaculation |
|
Date of first enrolment:
|
January 2005 |
|
Target sample size:
|
138 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00219635 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
|
|
Phase:
|
Phase 2/Phase 3
|
|
|
Countries of recruitment
|
|
Australia
|
Canada
|
United Kingdom
|
United States
| | | | |
|
Contacts
|
|
Name:
|
Pfizer CT.gov Call Center |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Pfizer |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Premature ejaculation as defined by DSM-IV
Exclusion Criteria:
- History of erectile dysfunction
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Male
|
|
Health Condition(s) or Problem(s) studied
|
|
Ejaculation
|
|
Intervention(s)
|
|
Drug: UK-390,957
|
|
Primary Outcome(s)
|
|
Assessment of efficacy and safety
|
|
Secondary Outcome(s)
|
|
Assessment of quality of sexual life
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|